Escientia Switzerland becomes Primopus
The Indian company Deccan Fine Chemicals is acquiring Escientia Switzerland and renaming it as Primopus AG. The new owner announces investments in the Basel Area production facility. The Swiss subsidiary of America’s Escientia Life Sciences Group was established in the Basel region in 2020.
Primopus, formerly Escientia Switzerland, is based at the Getec Park in Muttenz (img: Getec Park.swiss)
Deccan Fine Chemicals Private Ltd has announced the acquisition of Escientia Switzerland AG. In future, it will be called Primopus. Escientia, the Swiss subsidiary of the U.S. company Escientia Life Sciences Group, was established in 2020 with the support of Standortförderung Baselland and the location and innovation promotion agency Basel Area Business & Innovation.
According to a press release, Deccan, one of the world’s largest contract development and manufacturing organizations (CDMO companies), will be investing in a production plant taken over from Novartis spanning 17,000 square meters as part of this acquisition. It is expected to become operational in the second half of 2023.
Supply chain for pharmaceutical industry
According to the information provided, Primopus will focus on providing a hybrid supply chain for the pharmaceutical industry from its location at Getec Park in Muttenz in the canton of Basel-Landschaft. This will be linked to Deccan’s three large fine chemical sites in India. Furthermore, Deccan has announced that Primopus will further develop its research and development capacities.
Marcel Velterop has been named as the CEO. He commented that he is certain that bridging the skills and capabilities of the Swiss operation with the large talent and capacity pool in India will bring unique value and assurance to global players in the pharma supply chain, especially in the current geopolitical environment.
Share this article
You may also be interested in
Evolva launches new line for manufacturers of personal care products
Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...Read More
Record figure for startups in the Basel Area
Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...Read More
Noema Pharma raises 103 million Swiss francs from investors
Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....Read More
Why CDMO companies choose the Basel Area as their location
Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...Read More
Basel still the most attractive small city for business in Europe
As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...Read More
Ariceum Therapeutics establishes subsidiary in Basel
The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...Read More